CR20230427A - Compuestos inhibidores de fgfr3 - Google Patents

Compuestos inhibidores de fgfr3

Info

Publication number
CR20230427A
CR20230427A CR20230427A CR20230427A CR20230427A CR 20230427 A CR20230427 A CR 20230427A CR 20230427 A CR20230427 A CR 20230427A CR 20230427 A CR20230427 A CR 20230427A CR 20230427 A CR20230427 A CR 20230427A
Authority
CR
Costa Rica
Prior art keywords
fgfr3
inhibiting compounds
achondroplasia
fibrosis
saddan
Prior art date
Application number
CR20230427A
Other languages
English (en)
Inventor
Andrew Karl Dilger
Desta Doro Bume
Shane Michael Walls
Kevin Ronald Condroski
Andrew Terrance Metcalf
Kaveri Balan Urkalan
Adedoyin David Abraham
Timothy Scott Kercher
Robert Alan Hazlitt
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20230427A publication Critical patent/CR20230427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona los compuestos de la fórmula: <!--[if gte mso 9]><xml> <o:OLEObject Type="Embed" ProgID="MDLDrawOLE.MDLDrawObject.1" ShapeID="_x0000_i1025" DrawAspect="Content" ObjectID="_1754985866"> </o:OLEObject></xml><![endif]-->, para uso en el tratamiento de la esclerosis sistémica, la fibrosis (p. ej., fibrosis pulmonar), la acondroplasia, la displasia tanatofórica (p. ej., tipo I), la acondroplasia grave con retraso del desarrollo y acantosis nigricans (SADDAN), el síndrome de Muenke o el cáncer.
CR20230427A 2021-03-04 2022-03-03 Compuestos inhibidores de fgfr3 CR20230427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156527P 2021-03-04 2021-03-04
PCT/US2022/018644 WO2022187443A1 (en) 2021-03-04 2022-03-03 Fgfr3 inhibitor compounds

Publications (1)

Publication Number Publication Date
CR20230427A true CR20230427A (es) 2023-09-26

Family

ID=80937162

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230427A CR20230427A (es) 2021-03-04 2022-03-03 Compuestos inhibidores de fgfr3

Country Status (32)

Country Link
US (3) US11878976B2 (es)
EP (1) EP4301468B1 (es)
JP (2) JP7480438B2 (es)
KR (2) KR20240148943A (es)
CN (1) CN117120439B (es)
AR (1) AR125588A1 (es)
AU (1) AU2022229380B2 (es)
BR (1) BR112023015519A2 (es)
CA (1) CA3210594A1 (es)
CL (1) CL2023002605A1 (es)
CO (1) CO2023011623A2 (es)
CR (1) CR20230427A (es)
DK (1) DK4301468T3 (es)
DO (1) DOP2023000176A (es)
EC (1) ECSP23066654A (es)
ES (1) ES3053601T3 (es)
FI (1) FI4301468T3 (es)
HR (1) HRP20251473T1 (es)
IL (1) IL304886B2 (es)
JO (1) JOP20230206A1 (es)
LT (1) LT4301468T (es)
MA (1) MA63601B1 (es)
MD (1) MD4301468T2 (es)
MX (1) MX2023010342A (es)
PE (1) PE20231563A1 (es)
PT (1) PT4301468T (es)
RS (1) RS67479B1 (es)
SI (1) SI4301468T1 (es)
SM (1) SMT202600089T1 (es)
TW (1) TWI820622B (es)
UA (1) UA130389C2 (es)
WO (1) WO2022187443A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3
EP4584270A1 (en) 2022-09-07 2025-07-16 Eli Lilly And Company Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN120530110A (zh) * 2022-11-30 2025-08-22 海南先声再明医药股份有限公司 杂环化合物、药物组合物及其应用
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤
WO2024137587A1 (en) * 2022-12-19 2024-06-27 Tyra Biosciences, Inc. Fgfr3 inhibitor compounds
EP4648763A2 (en) * 2023-01-10 2025-11-19 Cogent Biosciences, Inc. Compounds for fgfrs inhibitors
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2025034912A2 (en) * 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026027726A1 (en) 2024-07-31 2026-02-05 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of diseases such as cancer
WO2026027635A1 (en) * 2024-07-31 2026-02-05 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of diseases such as cancer
WO2026027643A1 (en) 2024-07-31 2026-02-05 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of diseases such as cancer
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途
CN120647648B (zh) * 2024-09-24 2026-03-06 上海辉棵生物医药有限公司 新fgfr3抑制剂化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009279936A1 (en) * 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
CN101833512A (zh) 2010-04-22 2010-09-15 中兴通讯股份有限公司 一种内存回收方法及其装置
US20140228349A1 (en) 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
SMT202100451T1 (it) * 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
NZ715747A (en) 2013-07-31 2017-03-31 Gilead Sciences Inc Syk inhibitors
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MX373169B (es) * 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
US10538517B2 (en) 2015-05-22 2020-01-21 Principia Biopharma, Inc. Quinolone derivatives as FGFR inhibitors
US10744139B2 (en) * 2016-09-01 2020-08-18 Nanjing Transthera Biosciences Co. Ltd. Inhibitors of fibroblast growth factor receptor and use thereof
CN107315291B (zh) 2017-07-19 2020-06-16 深圳市华星光电半导体显示技术有限公司 一种goa显示面板及goa显示装置
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020135878A1 (zh) * 2018-12-29 2020-07-02 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
CA3141424C (en) * 2019-06-14 2023-11-07 Zhengxia CHEN Fused ring compound as fgfr and vegfr dual inhibitor
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
JP2024099714A (ja) 2024-07-25
PT4301468T (pt) 2025-11-25
US20230095122A1 (en) 2023-03-30
US11878976B2 (en) 2024-01-23
DK4301468T3 (da) 2025-12-01
IL304886B2 (en) 2025-08-01
HRP20251473T1 (hr) 2026-01-02
MD4301468T2 (ro) 2026-01-31
EP4301468B1 (en) 2025-09-03
KR20240148943A (ko) 2024-10-11
EP4301468A1 (en) 2024-01-10
CN117120439A (zh) 2023-11-24
DOP2023000176A (es) 2023-09-29
AR125588A1 (es) 2023-08-02
FI4301468T3 (fi) 2025-11-28
MA63601B1 (fr) 2025-09-30
CN117120439B (zh) 2026-04-07
ECSP23066654A (es) 2024-02-29
LT4301468T (lt) 2025-12-29
PE20231563A1 (es) 2023-10-03
US20250122196A1 (en) 2025-04-17
WO2022187443A1 (en) 2022-09-09
US12209086B2 (en) 2025-01-28
SMT202600089T1 (it) 2026-03-09
MX2023010342A (es) 2023-09-15
AU2022229380B2 (en) 2025-05-08
KR102712801B1 (ko) 2024-10-04
CA3210594A1 (en) 2022-09-09
IL304886A (en) 2023-10-01
KR20230130170A (ko) 2023-09-11
UA130389C2 (uk) 2026-02-04
CL2023002605A1 (es) 2024-06-21
AU2022229380A1 (en) 2023-08-24
JP7480438B2 (ja) 2024-05-09
SI4301468T1 (sl) 2026-01-30
TW202402754A (zh) 2024-01-16
ES3053601T3 (en) 2026-01-23
JP2023554598A (ja) 2023-12-28
RS67479B1 (sr) 2025-12-31
TW202300491A (zh) 2023-01-01
US20240190870A1 (en) 2024-06-13
CO2023011623A2 (es) 2023-09-18
BR112023015519A2 (pt) 2023-10-03
TWI820622B (zh) 2023-11-01
JOP20230206A1 (ar) 2023-09-04
IL304886B1 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
CR20230427A (es) Compuestos inhibidores de fgfr3
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
MX2025002692A (es) Derivados de pirazolo[1,5-a]piridina e imidazo[1,2-a]piridina como inhibidores de fgfr3 para el tratamiento del cancer
JOP20180125B1 (ar) صيغة صيدلانية سائلة ثابتة
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
MX384239B (es) Correccion de error de enlace en sistema de memoria.
PH12017501948A1 (en) Novelty crystal of uracil compound
CY1118433T1 (el) Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης
BR112018075218A2 (pt) correia transportadora
TWD208773S (zh) 連接器組件之部分
EP3784269A4 (en) ANTI-INTEGRIN LIGANDS AND USES THEREOF
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.
GEAP202014974A (en) Physiologically balanced injectable formulations of fosnetupitant
MX2019008545A (es) Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa.
MX2020010446A (es) Tratamiento de inhibicion de corrosion para fluidos agresivos.
MX2021008560A (es) Métodos de tratamiento de la diarrea inducida por inhibidor de tirosina cinasa.
EA201792607A1 (ru) Подложка, снабженная тонкослойной системой с термическими свойствами, содержащей последний металлический слой и предпоследний окислительный слой
TWD208771S (zh) 連接器組件之部分
MX2021000040A (es) Formulaciones farmaceuticas estables de oximetazolina.
BR112018001251A2 (pt) ?métodos e superfície interna ou externa?
EA202190009A1 (ru) Производные бензимидазола и их применение в качестве ингибиторов idh1
MX2020010159A (es) Composiciones de creatina y/o creatinina y metodos relacionados.
WO2019018384A3 (en) STABILIZED BIOCHARGE PARTICLES AND POLYMER COMPOSITIONS COMPRISING THE SAME
MX392288B (es) Miembro de cadena con un abocardado de sello en angulo.
PL73017Y1 (pl) Osłona wewnętrzna do profili z podwójnym oszkleniem